Podcasts about Rahul

Technology isn't just a sector anymore—it's the driving force reshaping every industry. Whether companies are creating technology or adopting it to avoid disruption, understanding this transformation is crucial for investment success.Columbia Threadneedle's tech investment approach stands apart through its disciplined focus on three complementary buckets: moat-type businesses with sustainable competitive advantages, secular growth themes identified early, and value opportunities where market prices underestimate business quality. This balanced strategy has consistently generated top-tier returns, with their technology portfolio ranking in Morningstar's top third for 8 of the past 12 years.What truly distinguishes their approach is patience. With just 7% annual turnover, they allow investments in companies like Microsoft, Apple, Amazon, and NVIDIA to compound over many years. This long-term perspective proves especially valuable when navigating tech's inherent volatility. As portfolio manager Rahul explains, even AI—their largest investment theme since 2016—has experienced two 20% pullbacks in the last 18 months alone.Recent earnings revealed tech's continued strength, with mega-cap tech growing earnings 28% versus just 9% for the remainder S&P 493. Cloud infrastructure spending is projected to reach $390 billion this year, nearly nine times higher than a decade ago. While tariffs pose the most significant current risk, particularly for semiconductors, the team's diversified approach and deep research capabilities help manage these challenges.With technology now representing 31% of the S&P 500 and nearly half the Russell 1000 Growth Index, investors increasingly recognize the value of specialist management in this complex sector. Columbia Threadneedle's recently launched Select Technology ETF (SEMI) offers another vehicle to access their expertise alongside their established funds.Ready to enhance your portfolio with professional technology exposure? Visit Columbia Threadneedle's website to explore their SEMI ETF and discover how their research-driven approach can help navigate technology's opportunities and challenges.With ChatDOC, instantly analyze professional documents using AI — featuring word-level citations, chart/formula breakdowns, cross-file query, and full support for PDFs/epub/scanned files.Free version handles 10 documents (up to 3000 pages) and cross-searches 30 files.Click the link below to unlock +10 document slots : https://chatdoc.com?src=leadlaglive Sign up to The Lead-Lag Report on Substack and get 30% off the annual subscription today by visiting http://theleadlag.report/leadlaglive. Support the show

Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Gilberto Lopes, a thoracic medical oncologist from the Sylvester Cancer Center. Together, they dived into the latest updates on anti-EGFR drugs used in non-small cell lung cancer (NSCLC) with EGFR mutations. In this informative discussion, they covered: •⁠  ⁠The evolution of EGFR inhibitors, including Afatinib, Osimertinib, Amivantamab, and Lazertinib. •⁠  ⁠Common side effects associated with these treatments, such as diarrhea, skin toxicity, and infusion-related reactions. •⁠  ⁠Strategies for managing these side effects to improve patient quality of life and treatment adherence. •⁠  ⁠Insights from recent studies, including the SKIPirr trial and the MARIPOSA study, highlighting the benefits of new combinations and treatment approaches. Youtube: https://youtu.be/v6fb6nx0YY4 Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Join us as we explore how proactive management of side effects can maximize the effectiveness of these therapies and enhance patient outcomes. Don't forget to check out our other ToxCheck discussions, treatment algorithms, and conference highlights!

Demetrios, Sam Partee, and Rahul Parundekar unpack the chaos of AI agent tools and the evolving world of MCP (Model Context Protocol). With sharp insights and plenty of laughs, they dig into tool permissions, security quirks, agent memory, and the messy path to making agents actually useful.// BioSam ParteeSam Partee is the CTO and Co-Founder of Arcade AI. Previously a Principal Engineer leading the Applied AI team at Redis, Sam led the effort in creating the ecosystem around Redis as a vector database. He is a contributor to multiple OSS projects including Langchain, DeterminedAI, LlamaIndex and Chapel amongst others. While at Cray/HPE he created the SmartSim AI framework which is now used at national labs around the country to integrate HPC simulations like climate models with AI. Rahul ParundekarRahul Parundekar is the founder of AI Hero. He graduated with a Master's in Computer Science from USC Los Angeles in 2010, and embarked on a career focused on Artificial Intelligence. From 2010-2017, he worked as a Senior Researcher at Toyota ITC working on agent autonomy within vehicles. His journey continued as the Director of Data Science at FigureEight (later acquired by Appen), where he and his team developed an architecture supporting over 36 ML models and managing over a million predictions daily. Since 2021, he has been working on AI Hero, aiming to democratize AI access, while also consulting on LLMOps(Large Language Model Operations), and AI system scalability. Other than his full time role as a founder, he is also passionate about community engagement, and actively organizes MLOps events in SF, and contributes educational content on RAG and LLMOps at learn.mlops.community.// Related LinksWebsites: arcade.devaihero.studio~~~~~~~~ ✌️Connect With Us ✌️ ~~~~~~~Catch all episodes, blogs, newsletters, and more: https://go.mlops.community/TYExploreMLOps Swag/Merch: [https://shop.mlops.community/]Connect with Demetrios on LinkedIn: /dpbrinkmConnect with Rahul on LinkedIn: /rparundekarConnect with Sam on LinkedIn: /samparteeTimestamps:[00:00] Agents & Tools, Explained (Without Melting Your Brain)[09:51] MVP Servers: Why Everything's on Fire (and How to Fix It)[13:18] Can We Actually Trust the Protocol?[18:13] KYC, But Make It AI (and Less Painful)[25:25] Web Automation Tests: The Bugs Strike Back[28:18] MCP Dev: What Went Wrong (and What Saved Us)[33:53] Social Login: One Button to Rule Them All[39:33] What Even Is an AI-Native Developer?[42:21] Betting Big on Smarter Models (High Risk, High Reward)[51:40] Harrison's Bold New Tactic (With Real-Life Magic Tricks)[55:31] Async Task Handoffs: Herding Cats, But Digitally[1:00:37] Getting AI to Actually Help Your Workflow[1:03:53] The Infamous Varma System Error (And How We Dodge It)

Join us in this episode of the Oncology Brothers podcast as we dive deep into the rapidly evolving treatment landscape for small-cell lung cancer. Hosted by community oncologists Drs. Rahul and Rohit Gosain, we are thrilled to welcome Dr. Ticiana Leal, a thoracic medical oncologist from the Winship Cancer Institute - Emory University. In this episode, we covered: •⁠  Current treatment paradigm of small cell lung cancer, in localized setting and extensive stage. •⁠  ⁠We covered the recent approval of durvalumab in limited stage setting post chemoRT. •⁠  We touched on the role of growth factors, and how they get rarely utilized, and covered use of Trilaciclib. •⁠ Stressed the importance of immunotherapy in extensive stage with choices of Atezolizumab and Durvalumab, and touched on extended survival data with Atezolizumab •⁠  Talked about logistical issues and uptake of Tarlatamab post approval. •⁠  Stressed the importance of clinical trials to move the field ahead. Whether you're a practicing oncologist or simply interested in the latest advancements in cancer treatment, this episode is packed with valuable information to help guide your practice. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!

This episode, the chaos begins with names—Jim Sarbh explains the minimal effort behind his naming, while Amit Sadh reveals how his was the first thing that must’ve popped into his parents' heads. From there, it’s a deep dive into their backgrounds—Jim’s posh Mumbai schooling and expat education, and Amit’s roots in Lucknow and a couple other places, his dad’s sports legacy, and a shared alma mater with Cyrus. The trio bond over their football allegiances (Liverpool, Man Utd, Arsenal—civil war!), working on Pune Highway with Rahul and Bugs, and a surprising amount of love for biking, animals, and awkward film screenings. We also get stories from their first films (Kai Po Che, Neerja), biking as therapy, illegal rallies, acting school camaraderie, and one wildly specific joke comparing Cyrus to a Cyprus tree. It's raw, real, and very Cyrus Says.See omnystudio.com/listener for privacy information.

In this episode of Marketing Mindset, I'm joined by Rahul, Head of Paid Marketing at a performance agency managing 7–9 figure brands. Why hook rate and CTR don't always predict performanceHis exact reporting structure for tracking new customer growthA scrappy influencer hack that landed his brand in front of A-list celebritiesHow to iterate creative the right way (hint: it's not headline swaps) We unpack what actually matters in creative testing, reporting, and scaling spend.Rahul shares:We also get real about creative fatigue, why Meta's definition of a “new” asset has changed, and what to track when performance drops, plus the one question you must ask founders before building a report.

Join us in this episode of the Oncology Brothers podcast as we dive deep into the rapidly evolving treatment landscape for metastatic non-small cell lung cancer (NSCLC) with actionable mutations in frontline therapy. Hosted by community oncologists Drs. Rahul and Rohit Gosain, we are thrilled to welcome Dr. Susan Scott, a thoracic medical oncologist from the Johns Hopkins Hospital. In this episode, we covered: •⁠  ⁠Common EGFR mutations and the latest treatment options, including osimertinib, amivantamab, and chemotherapy combinations. •⁠  ⁠The importance of comprehensive NGS testing and the need for retesting at progression. •⁠  ⁠Insights into managing side effects associated with various therapies, including the proactive management of cutaneous toxicities. •⁠  ⁠Treatment strategies for less common mutations such as ALK, ROS1, BRAF, and RET, along with their respective targeted therapies. •⁠  ⁠The role of immunotherapy in specific mutations and the importance of patient choice and preferences in treatment decisions. Whether you're a practicing oncologist or simply interested in the latest advancements in cancer treatment, this episode is packed with valuable information to help guide your practice. YouTube: https://youtu.be/LMYDAjZcn5w Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!

What happens when access to advanced AI models is no longer the real differentiator, and the true advantage lies in how businesses leverage their own data? At the AWS Summit in London, I sat down with Rahul Pathak, Vice President of Data and AI Go-to-Market at AWS, to unpack this question and explore how organisations are moving beyond experimentation and into large-scale generative AI adoption. Recorded live on the show floor, this conversation explores how AWS is supporting customers at every layer of their AI journey. From custom silicon innovations like Trainium and Inferentia to scalable services like Bedrock, Q Developer, and SageMaker, AWS is giving businesses the infrastructure, tools, and flexibility to innovate with confidence. Rahul shared how leading organisations such as BT Group, SAP, and Lonely Planet are already applying these tools to reduce costs, speed up development cycles, and deliver tailored experiences that would have been unthinkable just a few years ago. A key theme that emerged in our discussion is that data, not just models, is the true foundation of effective AI. Rahul explained why unifying data across silos is critical and how AWS is helping companies create more intelligent applications by connecting what they uniquely know about their business to powerful AI capabilities. We also addressed the operational realities of AI deployment. From moving proof-of-concept projects into production to meeting the growing demand for responsible AI, the challenges are shifting. Organisations are now focused on trust, security, transparency, and measurable value. If you're leading digital transformation and wondering how to scale AI solutions that deliver on business outcomes, this episode provides practical insight from someone at the center of the industry. How will your business stand out in a world where every company has access to AI models, but only a few know how to apply them with purpose?

This week on Cyrus Says, Cyrus catches up with theatre legends and long-time buddies Rahul daCunha and Bugs Bhargava—the brilliant minds behind the upcoming film Pune Highway. What starts as a movie promo somehow detours into Amul ad nostalgia, millionaire theories, their advertising days, and just maybe... a few drinks and drives (don’t try this at home). One of them even quit drinking. They’ve done plays, ads, life—and now a movie. Sort of. Pune Highway drops soon, find out if- Will Rahul sponsor the show? Will Bugs admit he's rich? And how deep does this decades-old friendship go? Watch till the end for some serious (and not-so-serious) bromance, behind-the-scenes madness, and vintage Cyrus Says mayhem.See omnystudio.com/listener for privacy information.

Welcome to the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Mark Awad, a world-renowned thoracic medical oncologist from Memorial Sloan Kettering. Together, they dived deep into the treatment landscape for metastatic non-small cell lung cancer (NSCLC) without actionable mutations in frontline settings. Episode Highlights: •⁠  ⁠The importance of next-generation sequencing (NGS) and PD-L1 levels in treatment decision-making. •⁠  ⁠Current treatment options for patients with high PD-L1 scores, including single-agent immunotherapy. •⁠  ⁠Strategies for patients with low or intermediate PD-L1 scores, including chemotherapy combined with immunotherapy. •⁠  ⁠Discussed KRAS G12C and HER2 positive disease in second-line settings, including the latest approved therapies. •⁠  ⁠Insights into the potential side effects and considerations when transitioning from immunotherapy to targeted therapies. Join us as we explored the complexities of treating metastatic NSCLC and the ongoing need for clinical trials and biomarker discovery. Don't forget to check out our other episodes for more insights on treatment algorithms and recent FDA approvals! Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!

“Any sufficiently advanced technology is indistinguishable from magic.”In this episode of The Neon Show, Vishwa (Co-founder of ZenDuty) is joined by Rahul Sasi (Co-founder of CloudSEK) and Ananda Krishna (Co-founder of Astra Security). They share how AI feels magical now. And how as founders they are trying to sprinkle this magic everywhere from how building products to building teams and everything that matters.-------------00:00 Everything is being Reimagined!00:41 Meet the New Hosts01:08 Founders' Biggest Time Killer05:10 Why entrepreneurs should fail fast?11:19 Will your job inevitably change?17:40 How AI has reimagined engineering jobs?19:13 PMs & Designers have New workflows20:35 Why everyone should learn to Prompt?24:14 Is your team using AI Budgets efficiently?26:59 Do people trust AI chatbots?32:18 Does sales still need humans?35:53 Do we expect empathy from AI?-------------Check us out on:Website: https://neon.fund/Instagram: https://www.instagram.com/theneonshoww/LinkedIn: https://www.linkedin.com/company/beneon/Twitter: https://x.com/TheNeonShowwConnect with Siddhartha on:LinkedIn: https://www.linkedin.com/in/siddharthaahluwalia/Twitter: https://x.com/siddharthaa7-------------This video is for informational purposes only. The views expressed are those of the individuals quoted and do not constitute professional advice.Send us a text

In this episode of the FHS Podcast, Marina Franolic speaks with Rahul Chaudhary, Managing Director & CEO of CG Corp Global and CG Hospitality Holdings. Rahul shares the bold investment strategy behind CG's presence in nearly 200 hotels across emerging markets — from Sri Lanka and India to the Middle East and Africa. He reflects on building through conflict, the rise of wellness as the new luxury, and why sustainability and digitisation are redefining hospitality. The conversation also touches on geopolitical challenges, tourism's power to unify, and CG's mission to create purposeful travel experiences rooted in simplicity, authenticity, and resilience.

In this episode of the Oncology Brothers podcast, Drs. Rahul & Rohit Gosain wrap up their three-part CME series on HER2-positive biliary tract cancer. Joined by Dr. Rachna Shroff, they delved into the critical topic of managing adverse events associated with treatments like TDXD and Zanidatamab. The discussion covered: •⁠  ⁠Overview of the treatment landscape for biliary tract cancer •⁠  ⁠Common side effects of TDXD, including interstitial lung disease, nausea, and fatigue •⁠  ⁠Management strategies for adverse events, including dose reductions and supportive care •⁠  ⁠Insights on Zanidatamab, its side effects, and infusion-related reactions •⁠  ⁠The importance of biomarker testing and patient-centered care in treatment decisions Tune in to gain valuable insights on how to improve patient quality of life while navigating the complexities of HER2-positive biliary tract cancer treatments. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!

SpectraMedix helps health plans and systems navigate value-based contracts with technology that enhances administration, provider support, and data-driven decisions. In this episode, Rahul Lakhanpal, Chief of Staff, and Sean Kelly, Senior Vice President of Growth and Business Development at SpectraMedix, discuss how their organization is driving change in healthcare by focusing on value-based contract administration and management. They share insights into how SpectraMedix's platform helps health plans and health systems administer contracts, track performance, and translate contract terms into actionable insights for providers. Rahul and Sean also highlight how their technology differentiates itself by filtering information through the prism of the value-based contract, enabling better decision-making and improved outcomes in the evolving landscape of value-based care. Tune in and learn how SpectraMedix is transforming value-based care through contract administration, provider enablement, and data-driven insights! Resources: Connect with and follow Rahul Lakhanpal on LinkedIn. Follow and connect with Sean Kelly on LinkedIn. Learn more about SpectraMedix on their LinkedIn and website.

Download Porter Here: https://app.adjust.com/1ocl2aaeT&C applyGuest Suggestion Form: https://forms.gle/bnaeY3FpoFU9ZjA47Disclaimer: This video is intended solely for educational purposes and opinions shared by the guest are his personal views. We do not intent to defame or harm any person/ brand/ product/ country/ profession mentioned in the video. Our goal is to provide information to help audience make informed choices. The media used in this video are solely for informational purposes and belongs to their respective owners.Order 'Build, Don't Talk' (in English) here: https://amzn.eu/d/eCfijRuOrder 'Build Don't Talk' (in Hindi) here: https://amzn.eu/d/4wZISO0Follow Our Whatsapp Channel: https://www.whatsapp.com/channel/0029VaokF5x0bIdi3Qn9ef2JSubscribe To Our Other YouTube Channels:-https://www.youtube.com/@rajshamaniclipshttps://www.youtube.com/@RajShamani.Shorts

#nationalinterest ‘The announcement of caste census has come in the build-up to the Bihar elections. The census may conclude just ahead of the Uttar Pradesh elections. The reason we call this move a bad idea is because nobody has figured out what to do with the data, except Rahul Gandhi'— Watch this week's #NationalInterest with Shekhar Gupta --------------------------------------------------------------------------------------------- Read this week's National Interest: https://theprint.in/national-interest/caste-census-is-a-bad-idea-whose-time-has-come-much-worse-lies-ahead/2613185/ --------------------------------------------------------------------------------------------- To visit ThePrint Store: https://store.theprint.in/ --------------------------------------------------------------------------------------------- Produced By: Mahira Khan

In this Telugu Podcast episode, we sit down with Rahul Attuluri to decode the real problems and opportunities faced by India's youth today–AI, UPSC, Education Reform, Gig Economy & Career Building. From AI revolution downgrading IT jobs to the gig economy impact on graduates (Zepto, Swiggy, Rapido), and the hidden traps in UPSC preparation, Rahul shares brutally honest insights.We dive deep into how India's brightest talents are getting stuck chasing marks over real skills, how parenting mindsets and outdated education systems are misguiding students, and why the future belongs to thinkers, not just toppers. Rahul talks about his journey of building NxtWave into a ₹2000+ Cr valued company, disrupting education with NIAT, and solving the true problem — transforming thousands of lives with skill-first learning.This conversation also covers important topics like the fake certificate mafia, IIT vs non-IIT mindset, AI's role in future wealth creation, and why continuous upskilling (not just degrees) is the real key to success. We discuss the stark contrast between China investing in AI and tech vs India's obsession with food-tech startups, and what needs to change to build a powerful, future-ready India.If you're a student, working professional, parent, entrepreneur, or someone passionate about career growth, tech disruption, and education reform in India, this episode might be for you. 

Listen to Editor Shafeeque V B speaks about his experience working with the legendary actor Mohanlal in the latest movie 'Thudarum'.#ShafeequeVB #FilmEditor #thudarum #clubfm

This episode is a playbook for any curious 20-something in India dreaming of building the next big consumer electronics brand. Whether it's smartphones, earbuds, AI-powered glasses or health wearables, we dig into what it really takes to break into, and survive, this highly competitive space.I sat down with three brilliant minds in the game who've actually done it: Carl Pei (Co-Founder, Nothing), Rahul Sharma (Co-Founder, Micromax), and Amit Khatri (Co-Founder, Noise). We tried to decode the what, how, and WTF of this industry—from regulations and the fairness of trade tariffs, to startup realities and what disruption might look like next.You might just spot the next big idea as they share some untapped opportunities waiting to be built in this sector.Resource Document: https://iridescent-party-a15.notion.site/Consumer-Electronics-Resource-Document-1e1aef3ec3e980f29b86dd9bae34410dTimestamps:00:00 - Intro01:12 - How Apple sparked Carl's love for tech05:05 - The reason for Y Combinator's success07:28 - Carl's ‘lazy genius' approach towards his career15:05 - How Nothing differentiated itself16:36 - US tariff's impact on China, India & the industry (Note: Since this episode was recorded before recent changes to global trade & tariff policies, some views may not reflect current regulations.)22:10 - Carl's philosophical views on life24:23 - Rahul's journey & the roots of his entrepreneurial spirit29:30 - Micromax's early days: From payphones to GSM innovation38:23 - How traveling to villages led to Micromax's success50:47 - Competing with China & Micomax's manufacturing pivot1:00:00 - Apple's vertical integration strategy: Lessons for companies & governments1:05:00 - Learnings from Rahul's risk-taking & resilience1:09:00 - Amit's journey from education to building Noise1:23:34 - Roadmap for 20-somethings entering the electronics industry01:41:47 - Identifying gaps in the commodity market1:48:02 - Disruption in smartphones through design and AI opportunities1:57:40 - Today's youth vs. yesterday's corporations2:01:13 - Building India's supply chain & unlocking its market opportunity2:07:21 - An electronics launchpad for young entrepreneurs2:16:45 - India's semiconductor push & restarting efforts2:22:26 - Future of TV: One UI for all streaming apps?2:25:41 - Can India build a global ecosystem in electronics?2:35:58 - Health wearables & EdTech opportunities2:42:44 - Advice for 20-somethings who want to break into this industry#NikhilKamath - Investor & EntrepreneurTwitter: https://x.com/nikhilkamathcioLinkedIN: https://www.linkedin.com/in/nikhilkamathcio/ Instagram: https://www.instagram.com/nikhilkamathcio/ Facebook: https://www.facebook.com/nikhilkamathcio/ #CarlPei - CEO & Co-Founder, NothingTwitter: https://x.com/getpeidLinkedIN: https://www.linkedin.com/in/getpeid/Instagram: https://www.instagram.com/getpeid/Facebook: https://www.facebook.com/getpeid/ #RahulSharma - Co-Founder, MicromaxTwitter: https://x.com/rahulsharma LinkedIN: https://www.linkedin.com/in/rahul-sharma-83038634a/ #AmitKhatri - Co-Founder, NoiseTwitter: https://x.com/iamamitkhatri LinkedIN: https://www.linkedin.com/in/iamamitkhatri/Instagram: https://www.instagram.com/itsamitkhatri/

The healthcare system is broken — but Dr. Rahul Iyengar, (M.D.) isn't waiting around to fix it. In this eye-opening episode, we sit down with the founder of Members Health Co. to expose why traditional health insurance is failing us, how the medical system keeps people sick, and what it really means to live a healthy, empowered life.We talk about: ✅ The scam behind health insurance✅ Why doctors are burned out and patients are overlooked✅ A new model of care that puts YOU at the center✅ What you can do today to take control of your healthIf you've ever felt like the system isn't built for your well-being — this one's for you.Join the BA Family & follow us on Instagram.Check out the visual on Youtube. Join the free newsletter where you get exclusive access to mindset tips, events and a network of like minded individuals. The #1 Non-Synthetic Supplement for anti-aging, skin, sleep, libido & recovery. Use code "breathinair"

Rahul Vohra (Founder and CEO at Superhuman) joins SaaStock's Alex Theuma to discuss how Superhuman stayed ahead of the generative AI wave, how they're shaping the future of productivity with autonomous email agents, and why great products that delights users — not flashy marketing — are the key to viral growth. Rahul also opens up about the loneliness of being a CEO, his meditation practices, and the game design principles behind Superhuman's success. Check out the other ways SaaStock is helping SaaS founders move their business forward: 

This is my conversation with Rahul Sonwalkar, founder of Julius AIJulius is an AI data scientist loved by millions of users.Timestamps:0:33 Building his own email service 3:03 Trying to build a social network 4:01 Launching Podcast comments dot com 7:16 Unambitious people & founding Waterview10:49 Bill Gates & Napoleon 13:42 Truck tracking startup 17:09 Sam Walton 20:00 Early versions of Julius 27:59 Why startups die33:21 Growing from 5k to 500k users35:22 Everyone answers support tickets 38:22 Hiring for high-slope 40:22 Asking for what you want

This week, we have Rahul Sonwalkar, Founder and CEO of Julius, on the show. Julius is your AI Data Scientist, where users can quickly analyze, visualize, and transform data.Rahul covers his journey from traveling across the country to hackathons in college, the importance of not being afraid of failing as a founder, how Rahul seeks out mentors, the four key ways Julius delivers value, and how Julius continues to add AI to data analysis.We also cover the decision to start selling bottoms up, how that enabled revenue in the early days, and how smarter models directly benefit Julius.Episode Chapters:Undergrad at UT Dallas - 1:47Being okay with being wrong - 4:18Overcoming ego - 7:15The Julius DNA - 9:20Your AI data analyst - 12:15Building trust with Julius - 15:30Maintaining infrastructure - 19:20Building out new features - 22:32Two kinds of AI startups - 27:13The next wave of SEO - 29:07Assessing talent - 32:12 Quick fire round - 33:26As always, feel free to contact us at partnerpathpodcast@gmail.com. We would love to hear ideas for content, guests, and overall feedback.This episode is brought to you by Grata, the world's leading deal sourcing platform. Our AI-powered search, investment-grade data, and intuitive workflows give you the edge needed to find and win deals in your industry. Visit grata.com to schedule a demo today.Fresh out of Y Combinator's Summer batch, Overlap is an AI-driven app that uses LLMs to curate the best moments from podcast episodes. Imagine having a smart assistant who reads through every podcast transcript, finds the best parts or parts most relevant to your search, and strings them together to form a new curated stream of content - that is what Overlap does. Podcasts are an exponentially growing source of unique information. Make use of it! Check out Overlap 2.0 on the App Store today.

Join us for an insightful episode of the Oncology Brothers podcast as we dive into the fast-evolving landscape of HER2-positive non-small cell lung cancer (NSCLC). In this first part of the two-part series, Drs. Rahul and Rohit Gosain were joined by Dr. Devika Das, a thoracic medical oncologist, and Dr. Fernando Lopez-Rios, a pathologist, to discuss the critical importance of testing and identifying HER2 alterations in lung cancer patients. In this episode, we covered: •⁠  ⁠The significance of HER2 alterations in NSCLC and how they differ from breast and gastric cancers. •⁠  ⁠The complexities of biomarker testing, including NGS, IHC, and FISH amplification. •⁠  ⁠Patient characteristics and phenotypes associated with HER2-positive disease. •⁠  ⁠The current testing workflows in clinical practice and the role of liquid biopsies. •⁠  ⁠Insights into the treatment landscape for HER2-positive NSCLC, including recent FDA approvals and ongoing clinical trials. Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode provides valuable information on the integration of precision medicine in lung cancer treatment. YouTube: https://youtu.be/gMi-sflQyQo Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for the next episode, where we will explore treatment options for HER2-positive non-small cell lung cancer in greater detail!

Sonia - Rahul in Big Trouble | Secret Modi Meeting with Top Leaders | Anupam K Singh Inside News

Rahul Kanwal और Sudhir Chaudhry का Career खतरे में | NDTV vs AAJ TAK में नया Twist | DD News

Listen to the latest updates from India. 16/04/25

Rahul Pangam — Entrepreneur, AI Strategist, and Founder

Concern about inequality is fine but will our government re-distribute income? What exactly do we propose to solve unemployment?The Congress has a history of 140 years and the BJP just 45, but does today's youth care? Shashi Tharoor asks probing questions but Gandhi's Congress won't answer. ThePrint Political Editor DK Singh explains why. --------------------------------------------------------------------------------------------- To visit ThePrint Store: https://store.theprint.in/ --------------------------------------------------------------------------------------------- Produced by: Mahira Khan

For our latest Uncrewed Views podcast, Jeremiah Karpowicz, Editorial Director of Commercial UAV News, talks with Rahul Sidhu, VP of Aviation at Flock Safety. They discuss the history of drone technology in public safety, creating a balance between safety and privacy, and issues around compliance, cybersecurity, and regulations.

Welcome back to the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Joshua Sabari, a thoracic medical oncologist from NYU, to discuss the latest findings from the European Lung Cancer Conference (ELCC) 2025. We dived into several key studies that are shaping the future of lung cancer treatment, including: • KEYNOTE-799: Exploring the combination of concurrent chemotherapy and radiation with the PD-1 inhibitor pembrolizumab for unresectable non-small cell lung cancer (NSCLC). • LAURA: The impact of osimertinib in patients with EGFR mutations post-chemoradiation therapy. • MARIPOSA: The promising results of amivantamab and lisertinib in the metastatic setting for EGFR-mutated NSCLC. • KRYSTAL-7: Investigating the use of KRAS G12C inhibitors in frontline therapy. Join us as we discuss the implications of these studies, the importance of next-generation sequencing (NGS), and how to manage side effects associated with these new therapies. YouTube: https://youtu.be/akoXXAUEl_8 Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in oncology! #Oncology #LungCancer #ELCC2025 #EGFR #KRAS #CancerResearch #Podcast

In which, we go back to the era when MS had Do Knees, and wonder if Umar Gul's Bowl-out inspired Digvesh Rathi, who signs off autographs for Travis Head to distribute to eager fans in supermarkets, and for Abhishek Sharma to flaunt after hitting match-winning 100s. In which Shreyas Iyer inspires order to the proceedings, and in which KL Rahul and Krunal Pandya follow in the illustrious footsteps of Anil Kumble, in two entirely different contexts.If nothing in the above paragraph made sense, don't panic - CSK's season is making even lesser sense.

Order my newest book Make Money Easy! https://lewishowes.com/moneyyouCheck out the full episode: greatness.lnk.to/1754"The dreaming brain is hyper emotional and hyper visual with dampened logic. It also locks down your body so you're temporarily paralyzed so the dreaming brain can let loose, be emotional, be wild." - Dr. Rahul JandialNeuroscientist Dr. Rahul Jandial takes us on a fascinating journey through the mysterious world of sleep paralysis and lucid dreaming. He explains the science behind those terrifying moments when you wake up unable to move—a phenomenon experienced by one-third of people worldwide. With remarkable clarity, Dr. Jandial breaks down how our brains transition between waking and dreaming states, revealing why these transitions sometimes overlap and create experiences so profound they've inspired cultural myths across civilizations.Delving deeper into the neuroscience of dreams, Dr. Jandial explores how our dreaming brain becomes hyper-emotional and hyper-visual while dampening logic. He unpacks the fascinating chemical processes that temporarily paralyze our bodies during sleep and how the misalignment between mind awakening and body releasing can create extraordinary experiences. Whether you've experienced sleep paralysis yourself or are curious about harnessing the power of lucid dreaming, this conversation offers invaluable insights into the complex relationship between your waking and dreaming consciousness.Sign up for the Greatness newsletter: http://www.greatness.com/newsletter

Jason and Rahul Sen Sharma, an expert on indexes from Index (INDXX), discuss global economic shifts, trade wars, and the stock market. His company tracks over $20 billion in index-based assets, aiding companies in creating indexes, ETFs, and funds. He emphasizes focusing on long-term macro trends over daily market noise, highlighting "re-globalization" as a key shift driven by supply chain vulnerabilities and a desire for friendly-shoring and near-shoring. While tariffs may offer short-term benefits to some countries like India and Mexico, the focus should be on transformative trends like EVs, battery tech, renewables, and critical metals for long-term investment. He also touches on the importance of understanding index rulebooks due to performance divergences and addresses concerns about the S&P 500's concentration, suggesting the marketplace will dictate the need for alternative weighting. https://www.indxx.com/ #Indexes #Economy #TradeWar #Tariffs #StockMarket #Globalization #Reglobalization #Friendshoring #Nearshoring #Investment #Finance #ETFs #MarketTrends #Macroeconomics #RahulSenSharma #INDXX Key Takeaways: 1:28 Meet Rahul 2:16 Broad strokes and taking a macro view 5:11 Reglobalization 7:49 Level playing field 9:43 Where do we go from here 13:16 A difference in indexes 16:24 Self-indexing and the active managers 20:50 The big picture perspective   Follow Jason on TWITTER, INSTAGRAM & LINKEDIN Twitter.com/JasonHartmanROI Instagram.com/jasonhartman1/ Linkedin.com/in/jasonhartmaninvestor/ Call our Investment Counselors at: 1-800-HARTMAN (US) or visit: https://www.jasonhartman.com/ Free Class:  Easily get up to $250,000 in funding for real estate, business or anything else: http://JasonHartman.com/Fund CYA Protect Your Assets, Save Taxes & Estate Planning: http://JasonHartman.com/Protect Get wholesale real estate deals for investment or build a great business – Free Course: https://www.jasonhartman.com/deals Special Offer from Ron LeGrand: https://JasonHartman.com/Ron Free Mini-Book on Pandemic Investing: https://www.PandemicInvesting.com    

About Rahul Lakhanpal:Rahul Lakhanpal is the Chief of Staff at SpectraMedix. He is focused on driving strategic initiatives and ensuring the company's alignment with market needs in the evolving landscape of value-based care.About Sean Kelly:Sean Kelly is the Senior Vice President of Growth and Business Development at SpectraMedix. He is responsible for leading the company's growth strategies and expanding its presence in the healthcare market.Things You'll Learn:SpectraMedix focuses on delivering a technology solution for value-based contract administration and management for health plans and health systems.The organization's platform enables different departments to come together, administer contracts, track performance, and identify opportunities for improvement.SpectraMedix differentiates itself by filtering information through the prism of the value-based contract, translating contract terms into actionable activities and measurements for providers.The company's technology helps health plans and health systems manage the increasing complexity of value-based contracts and make data-driven decisions.SpectraMedix emphasizes provider enablement by providing real-time financial incentives and making it easier for doctors to improve quality and reduce costs.Resources:Connect with and follow Rahul Lakhanpal on LinkedIn.Follow and connect with Sean Kelly on LinkedIn.Learn more about SpectraMedix on their LinkedIn and website.

Here's the thing: we all heard Sundar Pichai say that the easy wins in AI have faded and that we may see fewer headline‑grabbing releases from the big players over the next year. That comment feels like a red flag for momentum, but I see it as a green light for action.  In this episode, I chatted with Rahul Pradhan, VP of Product and Strategy at Couchbase, about how teams can take advantage of this pause to move projects from simple experiments into solid, production‑ready services. I ask why many organizations hesitate to send their data to public AI endpoints. Rahul explains that when you've invested years building data platforms, handing over your proprietary information—even in encrypted form—can feel like handing over the keys to your kingdom. He walks us through how running models inside your security perimeter keeps private data safe and brings up model accuracy since you can tailor inputs and scrub out noise before it ever reaches the inference engine. Next, we tackle the question of stability. Companies often assume that the path to a live service is straightforward once a pilot works. Rahul warns that managing GPUs, orchestrating models, and serving them at low latency all require skill sets that live at the crossroads of ML engineering and traditional software development. We round out our conversation by shifting focus from tools to teams. Technology alone cannot carry an AI initiative. We need leaders who set a clear vision, data stewards who govern every data flow, and developers who feel as comfortable writing database queries as they define training pipelines. Rahul offers thoughtful advice on building that culture and shares examples of industries—healthcare, financial services, and retail—where the most far‑reaching uses of AI are taking root. If you're wondering how to push your proof of concept into a robust service that customers depend on, this episode is for you. I promise you'll come away with ideas you can apply tomorrow and a fresh view of why a little breathing room in AI releases can become the launch pad for your subsequent big success.    

Welcome to another episode of the Oncology Brothers! In this episode, Drs. Rahul and Rohit Gosain are joined by their brother, Dr. Timothy Brown from UT Southwestern, to discuss the latest treatment paradigms for upper gastrointestinal (GI) malignancies, specifically focusing on esophageal and gastroesophageal junction adenocarcinoma, as well as gastric cancer. Episode Highlights: •⁠  ⁠Early Disease Management: perioperative FLOT versus concurrent chemoradiation. •⁠  ⁠Adjuvant Nivolumab: Insights from the Checkmate 577 trial and its implications for patients with residual disease post-chemoradiation. •⁠  ⁠Biomarker Testing: The importance of testing for MSI, HER2, Claudin 18.2, and PD-L1 to guide treatment decisions in metastatic settings. •⁠  ⁠Patient-Centered Care: Emphasizing the significance of shared decision-making and multidisciplinary approaches in managing complex cases. Join us as we unpack the nuances of upper GI malignancies and share key takeaways from recent studies and clinical practices.  YouTube: https://youtu.be/UNyi71u2wIw Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates on treatment algorithms and oncology insights!  

Union Pacific EVP and Chief Information Officer Rahul Jalali shares how the storied railroad is implementing technology, from shipment visibility to the physics simulator that keeps UP's trains from derailing. Learn more about your ad choices. Visit megaphone.fm/adchoices

There are certain traits that make some real estate investors more successful than others. Andrew and Rahul have been helping people build their real estate dreams for over a decade, so they've seen every type of investor. In this video, they'll go over some of the common traits found in the most successful investors. They'll also share their outlook on the real estate market.The Cashflow For Life podcast is about one thing: using real estate investing as a tool to create consistent cashflow every month for the rest of your life. Our mission is to help everyone in America buy their first 5 properties in the next 2 years, and have them paid off in 7 years. This is the 2-5-7 Cashflow For Life philosophy. Tune in to witness how ordinary people in our community have put this philosophy into action to increase their net worth and create consistent monthly cashflow as they continue their journey to build wealth for themselves and their families.==============Connect with us! ==============Facebook: @andrewholmesrealestate IG: @andrewholmesre

Welcome to another episode of the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain continue their ToxCheck series, focusing on the management of side effects associated with treatments for pancreatic cancer. Join us as we dive deep into the use of key drugs such as 5-FU, oxaliplatin, irinotecan, liposomal irinotecan, and the combination of gemcitabine and nab-paclitaxel. We are joined by esteemed guests Dr. Rachna Shroff from the University of Arizona and Dr. Midhun Malla from the University of Alabama, who share their insights and clinical pearls on managing the challenging side effects of these therapies. Key topics discussed include: •⁠  ⁠The utility of 5-FU bolus and leucovorin in treatment regimens •⁠  ⁠Managing common side effects like diarrhea, mucositis, and neuropathy •⁠  ⁠The importance of preemptive strategies in side effect management •⁠  ⁠Insights on liposomal irinotecan and its tolerability •⁠  ⁠The impact of gemcitabine and nab-paclitaxel on quality of life Whether you're a healthcare professional or someone interested in oncology, this episode provides valuable information on optimizing treatment while maintaining patient quality of life. YouTube: https://youtu.be/KByOGRpzFMQ Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to check out our other ToxCheck episodes on antibody drug conjugates, CAR-T, and anti-EGFR drugs used in colorectal cancer. Subscribe for more insights from the Oncology Brothers!  

Send us a textIn this episode of The Bearded Mystic Podcast, host Rahul N Singh delves into the concept of shadow work and its importance in the journey toward self-realization and enlightenment. He argues that shadow work must be done before enlightenment to prepare the mind for understanding one's true nature. Rahul discusses the four prerequisites required for spiritual growth and sheds light on how shadow work helps in recognizing and dealing with unconscious patterns, emotional attachments, and psychological shadows. He explores the role of discernment, detachment, mastery of senses, and the desire for liberation in overcoming these shadows. By integrating Advaita Vedanta teachings, the podcast provides a comprehensive guide to dealing with inner turmoil and recognizing the true self that exists beyond the mind's narratives.00:00 Introduction to The Bearded Mystic Podcast00:13 Understanding Shadow Work02:02 The Role of Vivek in Spirituality05:40 Dealing with Psychological Shadows08:01 Practicing Detachment13:33 Mastering the Mind and Senses19:10 Withdrawing from Distractions22:16 Enduring Pain and Discomfort23:35 Expressing and Managing Anger25:54 Faith in the Teachings and Path26:48 Inner Focus and Stillness28:12 Desire for Liberation29:58 Practical Scenarios and Responses36:34 The Importance of Shadow Work41:07 Final Thoughts and ConclusionJoin our Discord Server: https://discord.gg/hnRf7wESwX Visit my website: https://www.thebeardedmysticpodcast.com/Buy The Bearded Mystic Podcast Merch: https://thebeardedmysticpodcast.myshopify.com/Want a one-on-one spiritual discussion with The Bearded Mystic - book here: https://www.thebeardedmysticpodcast.com/p/spiritual-discussion/Subscribe to The Bearded Mystic Podcast channel: https://www.youtube.com/ @TheBeardedMysticPodcastBecome a Patron: https://www.patreon.com/thebeardedmysticpodcastRahul on Bluesky:  https://bsky.app/profile/beardedmystic.bsky.socialSupport the show

(Barre Center for Buddhist Studies)

Rahul Vohra is the founder and CEO of Superhuman. Prior to Superhuman, Rahul founded Rapportive, the first Gmail plug-in to scale to millions of users, which he sold to LinkedIn in 2012. He is also a prominent angel investor, and his fund has invested $50 million in over 120 companies, including Placer, Supabase, Mercury, Zip, ClassDojo, and Writer.What you'll learn:• The unexpected insight about virality Rahul gained from LinkedIn's head of growth.• Why Rahul restructured his entire executive team to spend 60% to 70% of his time on product, design, and marketing instead of the typical CEO responsibilities.• The counterintuitive approach to finding product-market fit using a methodical system inspired by Sean Ellis, and how this algorithmically determines your roadmap.• How manually onboarding every user (Superhuman had 20 full-time people doing this at peak) created superfans and allowed engineers to focus on product rather than onboarding flows.• The “Single Decisive Reason” framework for making better decisions by avoiding collections of weak justifications.• How Superhuman's AI features have evolved to create a truly intelligent email experience that works while you sleep.—Brought to you by:• Eppo—Run reliable, impactful experiments• Fundrise Flagship Fund—Invest in $1.1 billion of real estate• OneSchema—Import CSV data 10x faster—Find the transcript at: https://www.lennysnewsletter.com/p/superhumans-secret-to-success-rahul-vohra—Where to find Rahul Vohra:• X: https://x.com/rahulvohra• LinkedIn: https://www.linkedin.com/in/rahulvohra/• Email: Rahul@superhuman.com—Where to find Lenny:• Newsletter: https://www.lennysnewsletter.com• X: https://twitter.com/lennysan• LinkedIn: https://www.linkedin.com/in/lennyrachitsky/—In this episode, we cover:(00:00) Introduction to Rahul and Superhuman(05:00) The most pivotal moment in Rahul's career(07:01) The secret to virality(11:02) Superhuman's product evolution and core values(13:32) Overcoming slowdowns at scale(18:06) Time management and meditation(27:35) The role of a president(30:56) Attention to detail(43:00) Finding your unique position(47:32) The power of manual onboarding(52:37) Mastering product-market fit(59:33) Game design in business software(01:05:35) Contrarian pricing strategies(01:09:29) Leveraging AI(01:15:40) Transitioning to enterprise solutions(01:19:08) The Single Decisive Reason framework(01:22:32) Conclusion and final thoughts—Referenced:• Superhuman: https://superhuman.com/• Rapportive: https://techcrunch.com/2012/02/22/rapportive-linkedin-acquisition/• Elliot Shmukler on LinkedIn: https://www.linkedin.com/in/eshmu/• What Are ‘Whales' in Video Games: https://gamerant.com/video-games-whales-concept-term-explained/• Figma: https://www.figma.com/• Notion: https://www.notion.com/• Loom: https://www.loom.com/• How to use Team Comments to reimagine email collaboration: https://blog.superhuman.com/how-to-use-team-comments-to-reimagine-email-collaboration/• Rajiv Ayyangar's post on X about Superhuman: https://x.com/rajivayyangar/status/1816176308130570385• Transcendental Meditation: https://www.tm.org/• Laurent Valosek on LinkedIn: https://www.linkedin.com/in/laurent-valosek-18708b5a/• Peak Leadership Institute: https://www.peakleadershipinstitute.com/• Ed Sim's website: https://edsim.net/• Adelle Sans: https://fonts.adobe.com/fonts/adelle-sans• Comic Sans: https://en.wikipedia.org/wiki/Comic_Sans• Greenfield project: https://en.wikipedia.org/wiki/Greenfield_project• Why Mailbox died: https://www.theverge.com/2015/12/8/9873268/why-dropbox-mailbox-shutdown• Bill Trenchard on X: https://x.com/btrenchard• How Superhuman Built an Engine to Find Product-Market Fit: https://review.firstround.com/how-superhuman-built-an-engine-to-find-product-market-fit/• Using the Sean Ellis Test for Measuring Your Product-Market Fit: https://medium.productcoalition.com/using-sean-ellis-test-for-measuring-your-product-market-fit-c8ac98053c2c• Sean Ellis on LinkedIn: https://www.linkedin.com/in/seanellis/• The original growth hacker reveals his secrets | Sean Ellis (author of “Hacking Growth”): https://www.lennysnewsletter.com/p/the-original-growth-hacker-sean-ellis• The Trouble with Rewards: https://www.kornferry.com/insights/briefings-magazine/issue-13/519-the-trouble-with-rewards• The art and science of pricing | Madhavan Ramanujam (Monetizing Innovation, Simon-Kucher): https://www.lennysnewsletter.com/p/the-art-and-science-of-pricing-madhavan•  Van Westendorp Price Sensitivity Meter: https://en.wikipedia.org/wiki/Van_Westendorp%27s_Price_Sensitivity_Meter• AI-powered email for high-performing teams: https://superhuman.com/ai• Linear's secret to building beloved B2B products | Nan Yu (Head of Product): https://www.lennysnewsletter.com/p/linears-secret-to-building-beloved-b2b-products-nan-yu• Single Decisive Reason: decision-making for fast-scaling startups: https://blog.superhuman.com/single-decisive-reason-decision-making-for-fast-scaling-startups/• Reid Hoffman on LinkedIn: https://www.linkedin.com/in/reidhoffman/—Recommended books:• Positioning: The Battle for Your Mind: https://www.amazon.com/Positioning-Battle-Your-Al-Ries/dp/0071373586• Monetizing Innovation: How Smart Companies Design the Product Around the Price: https://www.amazon.com/Monetizing-Innovation-Companies-Design-Product/dp/1119240867—Production and marketing by https://penname.co/. For inquiries about sponsoring the podcast, email podcast@lennyrachitsky.com.—Lenny may be an investor in the companies discussed. Get full access to Lenny's Newsletter at www.lennysnewsletter.com/subscribe

Send us a textShort Summary: The science of cancer and immunity with Dr. Roychoudhuri, blending cutting-edge research with everyday implications like aspirin's role in fighting tumor metastasis.About the guest: Rahul Roychoudhuri, PhD is a Professor of Cancer Immunology at the University of Cambridge. His research bridges basic science and clinical applications, focusing on immune responses to cancer development and spread.Note: Podcast episodes are fully available to paid subscribers on the M&M Substack and everyone on YouTube. Partial versions are available elsewhere. Full transcript and other information on Substack.Episode Summary: The immune system's role in detecting and fighting cancer, particularly how cancer cells evade immunity through selection pressures and microenvironment manipulation. They explore cancer initiation via mutations and inflammation, metastasis mechanics, and a surprising link between low-dose aspirin and reduced cancer spread, spotlighting new research on T cells and thromboxane. The discussion ties in dietary fats, aspirin's anti-inflammatory and anti-clotting effects, and the potential for new therapies to prevent metastasis.Key Takeaways:The immune system constantly surveils and eliminates early cancer cells, but surviving cancers evolve to dodge detection.Inflammation can both spark cancer growth and be exploited by tumors to suppress helpful immune responses.Cancer metastasis, responsible for ~90% of cancer deaths, involves cells breaking off, traveling, and adapting to new sites.New research shows aspirin may curb metastasis by lowering thromboxane, a lipid-derived blood clotting factor.Human data hints aspirin reduces metastasis risk in cancers like breast and colorectal, but trials are ongoing.Daily low-dose aspirin (75-100 mg) is used for heart health, yet its cancer benefits need more study. 600 mg per day has been observed to reduce metastasis rates in colon cancer patients, but chronic use of that dose carries some risk (ulcers, bleeding).*Not medical advice.Support the showAll episodes, show notes, transcripts, etc. at the M&M Substack Affiliates: Lumen device to optimize your metabolism for weight loss or athletic performance. Use code MIND for 10% off. Readwise: Organize and share what you read. Athletic Greens: Comprehensive & convenient daily nutrition. Free 1-year supply of vitamin D with purchase. KetoCitra—Ketone body BHB + potassium, calcium & magnesium, formulated with kidney health in mind. Use code MIND20 for 20% off any subscription. MASA Chips—delicious tortilla chips made from organic corn and grass-fed beef tallow. No seed oils or artificial ingredients. Use code MIND for 20% off. For all the ways you can support my efforts

In this episode, Dr. Rahul Gupta, President of GATC Health, joins Scott Becker to discuss how AI and machine learning are transforming the speed, cost, and success rates of drug development.

In this episode, Dr. Rahul Gupta, President of GATC Health, joins Scott Becker to discuss his groundbreaking work in drug discovery using artificial intelligence. Dr. Gupta shares insights from his career, including his leadership in combating the opioid crisis, and explains how AI and machine learning are transforming the speed, cost, and success rates of drug development.

Join us for an insightful episode of the Oncology Brothers podcast as we dive deep into the world of renal cell carcinoma (RCC) with Dr. Katy Beckermann, the Medical GU Director of Cancer Research at Tennessee Oncology. In this episode, hosts Drs. Rahul & Rohit Gosain, practicing medical oncologists, discuss the latest advancements in RCC treatment, including: •⁠  ⁠The role of Pembrolizumab in the adjuvant setting based on the Keynote 564 study and its implications for early-stage disease. •⁠  ⁠Current treatment paradigms for metastatic RCC, including dual checkpoint inhibitors, TKI with immunotherapy, and single-agent options. •⁠  ⁠The importance of patient characteristics and IMDC risk categorization in treatment decisions. •⁠  ⁠Insights into sequencing therapies, including the use of Belzutifan for refractory disease and the management of side effects. •⁠  ⁠The role of ctDNA, PD-L1 testing, and NGS in RCC. Whether you're a community oncologist or simply interested in the latest in cancer care, this episode is packed with valuable information to help you stay informed and provide the best care for your patients. YouTube: https://youtu.be/Bbv9N7-YKIM Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and leave a review to let us know how we're doing and how we can continue to support you in the community!  

On the podcast today we have Rahul Bansal, CEO of rtCamp. He's here to talk about his journey from a blogger to running a large enterprise WordPress agency. Rahul discusses the nuances of working with enterprise clients, emphasising scalability and security. We get into rtCamp's growth, client acquisition strategies, and their unique training initiative attracting talent from colleges, focused on contributing to WordPress and fostering open-source advocacy. Rahul also highlights WordPress's adaptability, particularly with Gutenberg, in crafting robust, enterprise-level solutions while actively supporting the WordPress community. If you've ever considered what it takes to work with WordPress at the enterprise level, this episode is for you.

This Week in Startups is brought to you by…Lemon.io. Get 15% off your first 4 weeks of developer time at https://Lemon.io/twistNorthwest Registered Agent. Get more privacy, more options, and more done—visit northwestregisteredagent.com/twist today!Vapi. Go to Vapi.ai and use code Twist200 to get $200 in creditsToday's show: Jason interviews Rahul Vohra, CEO and founder of Superhuman, and Vlad Tenev, CEO and co-founder of Robinhood. This is a packed episode featuring founder tips, fun stories about how Superhuman and Robinhood got their start and much more!Timestamps:(0:00) Episode teaser(2:13) Product market fit and founder journeys(3:25) Jason's investment in Superhuman and market positioning(5:14) AI's role and features in Superhuman(10:25) Lemon.io. Get 15% off your first 4 weeks of developer time at https://Lemon.io/twist(14:37) Targeting users and competitive advantages(22:23) Evolution and new features of Superhuman(20:52) Northwest Registered Agent. Get more privacy, more options, and more done—visit northwestregisteredagent.com/twist today!(24:37) Tackling spam with Superhuman's AI(27:05) Custom auto labels and email classification(29:47) Vapi. Go to Vapi.ai and use code Twist200 to get $200 in credits(32:03) Superhuman's auto reminders and drafts(34:14) Vlad Tenev and the origins of Robinhood(39:31) Product design philosophies of Robinhood and Superhuman(49:29) Scaling design principles and investment decisions(52:31) Subjectivity in product design(55:14) Customer feedback in product development(1:00:00) Superhuman's subscription model and customer acquisition(1:05:11) PR strategies and news hijacking(1:08:33) Robinhood's waitlist and viral moments(1:12:06) Investment experiences with Robinhood(1:13:35) Navigating company valuation fluctuations(1:15:03) Influences on Vlad Tenev and new Robinhood desktop product(1:20:11) Diversification of Robinhood's business(1:22:02) Company resilience and employee reorganization(1:25:52) Crypto regulation and startup mentality(1:30:05) Investment trends among Robinhood users(1:31:12) Retail benefits for startups and capital raising challenges(1:34:04) Accreditation for private investing and solutionsSubscribe to the TWiST500 newsletter: https://ticker.thisweekinstartups.comCheck out the TWIST500: https://www.twist500.comSubscribe to This Week in Startups on Apple: https://rb.gy/v19fcpLinks from this episode:Check out Superhuman: https://superhuman.com/Check out Robinhood Legends: https://robinhood.com/us/en/legend/Article “How Superhuman Built an Engine to Find Product Market Fit**”:** https://review.firstround.com/how-superhuman-built-an-engine-to-find-product-market-fit/Check out Rick Rubin's book: https://www.amazon.ca/Creative-Act-Way-Being/dp/0593652886Article on Bezos and Washington Post: https://www.newsweek.com/bezos-makes-big-change-washington-post-opinion-focus-endorsed-musk-2036618Media Bias Chart: https://www.allsides.com/media-bias/media-bias-chartCheck out “Working Backwards” book about Amazon insights: https://www.amazon.ca/Working-Backwards-Insights-Stories-Secrets/dp/1250267595Check out Rahul's article on acquisition: https://www.linkedin.com/pulse/rip-mailbox-founders-how-stop-worrying-love-being-acquired-vohra/Follow Rahul:X: https://x.com/rahulvohraLinkedIn: https://www.linkedin.com/in/rahulvohra/Follow Vlad:X: https://x.com/vladtenevLinkedIn: https://www.linkedin.com/in/vlad-tenev-7037591b/Follow Jason:X: https://twitter.com/JasonLinkedIn: https://www.linkedin.com/in/jasoncalacanisThank you to our partners:(10:25) Lemon.io. Get 15% off your first 4 weeks of developer time at https://Lemon.io/twist(20:52) Northwest Registered Agent. Get more privacy, more options, and more done—visit northwestregisteredagent.com/twist today!(29:47) Vapi. Go to Vapi.ai and use code Twist200 to get $200 in credits